Proteins associated with risk include the activating proteins C3 and CFB and the control proteins CFH, CFI and the CFH-related proteins (CFHRs); indeed, intravitreal inhibition of the amplification loop with an inhibitor of CFD (lamaplizumab) is a strategy which showed promise in phase 2 studies of geographic atrophy and is currently being tested in phase 3 trials [33]. The gene discussed is CFD; the disease is atrophic macular degeneration.